Business Context and Reporting Period
Company: Neuronetics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 27, 2019
Event: Item 8.01 Other Events – Announcement of regulatory approval in Japan.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The material change reported is a regulatory milestone rather than a financial variance:
- Japan Reimbursement Approval: Japan's Central Social Insurance Medical Council (Chuikyo) approved the recommendation by the Ministry of Health, Labour and Welfare expert review panel.
- Scope: The approval provides reimbursement for the NeuroStar Advanced Therapy for the treatment of Major Depressive Disorder in adults.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) detailing the approval but does not include forward-looking guidance, financial outlook, or specific risk factors within the text of this 8-K.
Unusual Items: None reported beyond the regulatory approval event.
Investor Verification Checklist
- Verify the effective date of reimbursement implementation in Japan following the Chuikyo approval.
- Review the attached press release (Exhibit 99.1) for specific details on the reimbursement rate or coverage limits.
- Assess the potential impact of this approval on Neuronetics' international revenue projections in subsequent quarterly reports.